{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:54:30Z","timestamp":1782226470565,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","award":["Z-2\/CSP-32"],"award-info":[{"award-number":["Z-2\/CSP-32"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","award":["Z-3BC\/08"],"award-info":[{"award-number":["Z-3BC\/08"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>The aim of this study is to investigate the impact of lymph node metastases (LNM) detected on cervical <jats:sup>131<\/jats:sup>I single photon emission computed tomography\/computed tomography (SPECT\/CT) after the first radioiodine therapy (RAI) on complete response (CR) and progression-free survival (PFS) in patients with differentiated thyroid cancer (DTC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective study included 942 DTC patients who underwent cervical <jats:sup>131<\/jats:sup>I SPECT\/CT after their first RAI. LNM were categorized based on CT (enlarged\u2009\u2265\u20091\u00a0cm, small\u2009&lt;\u20091\u00a0cm) and <jats:sup>131<\/jats:sup>I uptake. CR and PFS were analysed using Kaplan\u2013Meier curves and Cox regression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Patients with no LNM had a shorter median time to CR (9.4\u00a0months) than those with LNM (44\u00a0months, HR 2.2; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and a lower risk of progression (median PFS not reached, HR 0.46; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Among patients with LNM, those with enlarged <jats:sup>131<\/jats:sup>I negative LNM had the longest time to CR (24\u00a0months, HR 0.36; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Patients with small LNM had a PFS similar to patients without LNM (median PFS not reached, HR 1.22; <jats:italic>p<\/jats:italic>\u2009=\u20090.54). Reoperation after first RAI (13.5\u00a0months) led to earlier CR than second RAI (median not reached) in patients with enlarged LNM. For small LNM, second RAI was associated with longer PFS than reoperation (38.4\u00a0months vs. not reached, HR 4.0; <jats:italic>p<\/jats:italic>\u2009=\u20090.02).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Patients without LNM on post-therapy <jats:sup>131<\/jats:sup>I SPECT\/CT have better chances for early CR and longer PFS. Patients with LNM benefit from early reoperations but treatment strategies should be tailored based on LNM characteristics.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-025-07187-1","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T10:29:18Z","timestamp":1742034558000},"page":"3170-3179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["131I SPECT\/CT provides prognostic information in patients with differentiated thyroid cancer"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3526-8601","authenticated-orcid":false,"given":"Marieke","family":"Heinrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Blickle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp E.","family":"Hartrampf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Hasenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Kosmala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kerscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Schlegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik A.","family":"Verburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"issue":"6","key":"7187_CR1","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1089\/thy.2017.0102","volume":"27","author":"RM Tuttle","year":"2017","unstructured":"Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer\/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? Thyroid. 2017;27(6):751\u20136. https:\/\/doi.org\/10.1089\/thy.2017.0102.","journal-title":"Thyroid"},{"issue":"2","key":"7187_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"7187_CR3","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1089\/thy.2009.0110","volume":"19","author":"DS Cooper","year":"2009","unstructured":"Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167\u2013214. https:\/\/doi.org\/10.1089\/thy.2009.0110.","journal-title":"Thyroid"},{"issue":"1","key":"7187_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020.","journal-title":"Thyroid"},{"issue":"2","key":"7187_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/thy.2006.16.109","volume":"16","author":"DS Cooper","year":"2006","unstructured":"Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Taskforce. Thyroid. 2006;16(2):109\u201342.","journal-title":"Thyroid"},{"issue":"12","key":"7187_CR6","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1007\/s00259-022-05935-1","volume":"49","author":"P Petranovi\u0107 Ov\u010dari\u010dek","year":"2022","unstructured":"Petranovi\u0107 Ov\u010dari\u010dek P, Kreissl MC, Campenni A, de Keizer B, Tuncel M, Vrachimis A, et al. SNMMI\/EANM practice guideline vs. ETA Consensus Statement: differences and similarities in approaching differentiated thyroid cancer management\u2014the EANM perspective. Eur J Nucl Med Mol Imaging. 2022;49(12):3959\u201363.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"4","key":"7187_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-0037-1622117","volume":"52","author":"F Verburg","year":"2013","unstructured":"Verburg F, Weber T, Luster M. 131I sodium-iodide versus 5 6Fe surgical steel. Which is better for lateral lymph node metastases in differentiated thyroid cancer patients? Nuklearmedizin. 2013;52(4):113\u20134.","journal-title":"Nuklearmedizin"},{"key":"7187_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3389\/fendo.2019.00671","volume":"10","author":"C Bouvet","year":"2019","unstructured":"Bouvet C, Barres B, Kwiatkowski F, Batisse-Lignier M, Chafai El Alaoui M, Kauffmann P, et al. Re-treatment With Adjuvant Radioactive Iodine Does Not Improve Recurrence-Free Survival of Patients With Differentiated Thyroid Cancer. Front Endocrinol (Lausanne). 2019;10:671. https:\/\/doi.org\/10.3389\/fendo.2019.00671.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"4","key":"7187_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1055\/s-0042-1750404","volume":"21","author":"E Cadena-Pi\u00f1eros","year":"2022","unstructured":"Cadena-Pi\u00f1eros E, Escobar JV, Carre\u00f1o JA, Rojas JG. Second Adjuvant Radioiodine Therapy after Reoperation for Locoregionally Persistent or Recurrent Papillary Thyroid Carcinoma. World J Nucl Med. 2022;21(4):290\u20135. https:\/\/doi.org\/10.1055\/s-0042-1750404.","journal-title":"World J Nucl Med"},{"issue":"6","key":"7187_CR10","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s00259-016-3593-0","volume":"44","author":"A Piccardo","year":"2017","unstructured":"Piccardo A, Puntoni M, Bottoni G, Treglia G, Foppiani L, Bertoli M, et al. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy. Eur J Nucl Med Mol Imaging. 2017;44(6):926\u201334. https:\/\/doi.org\/10.1007\/s00259-016-3593-0.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"7187_CR11","unstructured":"Avram AM, Giovanella L, Greenspan B, Lawson SA, Luster M, Van Nostrand D et al (2022) SNMMI procedure standard\/EANM practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: abbreviated version. Soc Nuclear Med"},{"issue":"2","key":"7187_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/(sici)1097-0347(199603\/04)18:2","volume":"18","author":"CJ Hughes","year":"1996","unstructured":"Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck. 1996;18(2):127\u201332. https:\/\/doi.org\/10.1002\/(sici)1097-0347(199603\/04)18:2.","journal-title":"Head Neck"},{"issue":"4","key":"7187_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/0002-9610(91)90147-6","volume":"162","author":"CR McHenry","year":"1991","unstructured":"McHenry CR, Rosen IB, Walfish PG. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg. 1991;162(4):353\u20136. https:\/\/doi.org\/10.1016\/0002-9610(91)90147-6.","journal-title":"Am J Surg"},{"issue":"6","key":"7187_CR14","doi-asserted-by":"publisher","first-page":"764","DOI":"10.4158\/ep.14.6.764","volume":"14","author":"RM Tuttle","year":"2008","unstructured":"Tuttle RM. Risk-adapted management of thyroid cancer. Endocr Pract. 2008;14(6):764\u201374. https:\/\/doi.org\/10.4158\/ep.14.6.764.","journal-title":"Endocr Pract"},{"issue":"12","key":"7187_CR15","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1089\/thy.2010.0178","volume":"20","author":"RM Tuttle","year":"2010","unstructured":"Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20(12):1341\u20139. https:\/\/doi.org\/10.1089\/thy.2010.0178.","journal-title":"Thyroid"},{"key":"7187_CR16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s00259-009-1315-6","volume":"37","author":"FA Verburg","year":"2010","unstructured":"Verburg FA, Stokkel MP, D\u00fcren C, Verkooijen RB, M\u00e4der U, van Isselt JW, et al. No survival difference after successful 131 I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37:276\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7187_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1089\/thy.2022.0542","volume":"33","author":"LB Walter","year":"2023","unstructured":"Walter LB, Scheffel RS, Zanella AB, Farenzena M, Faccin CS, Graudenz MS, et al. Active Surveillance of Differentiated Thyroid Cancer Metastatic Cervical Lymph Nodes: A Retrospective Single-Center Cohort Study. Thyroid. 2023;33(3):312\u201320. https:\/\/doi.org\/10.1089\/thy.2022.0542.","journal-title":"Thyroid"},{"issue":"2","key":"7187_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1530\/eje-12-0744","volume":"168","author":"MJ Jeon","year":"2013","unstructured":"Jeon MJ, Yoon JH, Han JM, Yim JH, Hong SJ, Song DE, et al. The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma. Eur J Endocrinol. 2013;168(2):219\u201325. https:\/\/doi.org\/10.1530\/eje-12-0744.","journal-title":"Eur J Endocrinol"},{"key":"7187_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.oraloncology.2018.10.041","volume":"87","author":"Y Sun","year":"2018","unstructured":"Sun Y, Gong J, Guo B, Shang J, Cheng Y, Xu H. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer. Oral Oncol. 2018;87:152\u20137. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.10.041.","journal-title":"Oral Oncol"},{"key":"7187_CR20","doi-asserted-by":"publisher","first-page":"1158581","DOI":"10.3389\/fendo.2023.1158581","volume":"14","author":"H Guo","year":"2023","unstructured":"Guo H, Zhang N, Hu Y, Zhang F, Huang T, Shen N. Radioactive iodine therapy strategies for distinct types of differentiated thyroid cancer: a propensity score-matched analysis. Front Endocrinol (Lausanne). 2023;14:1158581. https:\/\/doi.org\/10.3389\/fendo.2023.1158581.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"7187_CR21","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1210\/jc.2012-1533","volume":"97","author":"RC Webb","year":"2012","unstructured":"Webb RC, Howard RS, Stojadinovic A, Gaitonde DY, Wallace MK, Ahmed J, et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab. 2012;97(8):2754\u201363. https:\/\/doi.org\/10.1210\/jc.2012-1533.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"7187_CR22","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1007\/s00259-023-06239-8","volume":"50","author":"L Giovanella","year":"2023","unstructured":"Giovanella L, Milan L, Roll W, Weber M, Schenke S, Kreissl M, et al. Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2023;50(9):2767\u201374. https:\/\/doi.org\/10.1007\/s00259-023-06239-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"21","key":"7187_CR23","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1200\/jco.2014.59.8391","volume":"33","author":"MA Adam","year":"2015","unstructured":"Adam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, et al. Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer. J Clin Oncol. 2015;33(21):2370\u20135. https:\/\/doi.org\/10.1200\/jco.2014.59.8391.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07187-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07187-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07187-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:52:26Z","timestamp":1751435546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07187-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7187"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07187-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was waived by the local Ethics Committee of the Julius-Maximilians-University Wuerzburg in view of the retrospective nature of the study and all procedures being performed were part of the routine care (waiver no. 20231103 02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Author F.A. Verburg has received speaker and consultancy Fees from GE Healthcare (paid to the employer), speaker fees from Bayer (paid to the employer) and Consultancy fees von Immedica (paid to the employer).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}